Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBITDA Margin (2018 - 2025)

Cue Biopharma's EBITDA Margin history spans 8 years, with the latest figure at 346.53% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 8694.0% year-over-year to 346.53%; the TTM value through Sep 2025 reached 530.81%, down 6273.0%, while the annual FY2024 figure was 437.97%, 48438.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 346.53% at Cue Biopharma, down from 287.23% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 101.57% in Q4 2021 and bottomed at 50800.0% in Q2 2022.
  • The 5-year median for EBITDA Margin is 719.1% (2024), against an average of 4982.31%.
  • The largest annual shift saw EBITDA Margin crashed -5042472bps in 2022 before it surged 4984910bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 101.57% in 2021, then plummeted by -9416bps to 9666.23% in 2022, then soared by 92bps to 738.13% in 2023, then rose by 18bps to 602.54% in 2024, then soared by 42bps to 346.53% in 2025.
  • Per Business Quant, the three most recent readings for CUE's EBITDA Margin are 346.53% (Q3 2025), 287.23% (Q2 2025), and 2911.4% (Q1 2025).